


**Product Name** : AVL-292 besylate  
**Cat. No.** : PC-45402  
**CAS No.** : 1360053-81-1  
**Molecular Formula** : C<sub>28</sub>H<sub>28</sub>FN<sub>5</sub>O<sub>6</sub>S  
**Molecular Weight** : 581.6152  
**Target** : BTK  
**Solubility** : 10 mM in DMSO



## Biological Activity

AVL-292 besylate (Spebrutinib, CC-292) is a highly selective, covalent **Btk** inhibitor with IC<sub>50</sub> of <1 nM.

AVL-292 besylate (Spebrutinib, CC-292) also less potently inhibits Yes, c-Src, Brk, Lyn, and Fyn with IC<sub>50</sub>s of 723 nM, 1.729 μM, 2.43 μM, 4.4 μM, and 7.15 μM, respectively.

AVL-292 besylate (Spebrutinib, CC-292) shows anti-inflammatory activity in the collagen-induced arthritis model of autoimmune disease.

AVL-292 besylate (Spebrutinib, CC-292) also prevents NRG- and EGF-dependent growth factor-driven resistance to lapatinib in HER2(+) breast cancer cells.

## References

Evans EK, et al. *J Pharmacol Exp Ther*. 2013 Aug;346(2):219-28.

Eda H, et al. *Leukemia*. 2014 Sep;28(9):1892-901.

Wang X, et al. *Mol Cancer Ther*. 2016 Sep;15(9):2198-208.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com